T-cell receptor Vβ CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia

Leukemia

Volumn 22, Issue 6, 2008, Pages 1170-1174

  de Vries, A C H ^a   Langerak, A W ^b   Verhaaf, B ^b   Niemeyer, C M ^c   Stary, J ^d   Schmiegelow, K ^e   van Wering, E R ^f   Zwaan, C M ^a,f   Beishuizen, A ^a   Pieters, R ^a   van den Heuvel Eibrink, M M ^a,f  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CHARLES UNIVERSITY   (Czech Republic)

^e Rigshospitalet   (Denmark)

^f DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RNA; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR VBETA;

APLASTIC ANEMIA; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CHILD; CLONAL VARIATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; HETERODUPLEX ANALYSIS; HUMAN; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; RNA EXTRACTION;

EID: 45149128556     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.23     Document Type: Article

References (29)

1. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: Association between hematologic response and long-term outcome. JAMA 2003; 289: 1130-1135.
2. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365-1372.
3. Brodsky R. Acquired severe aplastic anemia in children: Is there a standard of care? Pediatr Blood Cancer 2004; 43: 711-712.
4. Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G et al. Immunosuppressive therapy for aplastic anemia in children: A more severe disease predicts better survival. Blood 2005; 106: 2102-2104.
5. Marsh JC. Results of immunosuppression in aplastic anaemia. Acta Haematol 2000; 103: 26-32.
6. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: An update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 95: 1931-1934.
7. Fuhrer M, Burdach S, Ebell W, Gadner H, Haas R, Harbott J et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): The SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group. Klin Padiatr 1998; 210 173-179.
8. Kojima S, Horibe K, Inaba J, Yoshimi A, Takahashi Y, Kudo K et al. Long-term outcome of acquired aplastic anaemia in children: Comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 2000; 111: 321-328.
9. Kardos G, Baumann I, Passmore SJ, Locatelli F, Hasle H, Schultz KR et al. Refractory anemia in childhood: A retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003; 102: 1997-2003.
10. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277-282.
11. Kook H, Risitano AM, Zeng W, Wlodarski M, Lottemann C, Nakamura R et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood 2002; 99 3668-3675.
12. Risitano AM, Kook H, Zeng W, Chen G, Young NS, Maciejewski JP. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry. Blood 2002; 100: 178-183.
13. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: Molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004; 364: 355-364.
14. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, Maciejewski JP. Molecular strategies for detection and quantitation of clonal cytotoxic T cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006; 108: 2632-2641.
15. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP et al. Severe aplastic anemia: A prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48 63-70.
16. Cantu Rajnoldi A, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I. Evaluation of dysplastic features in myelodysplastic syndromes: Experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol 2005; 84: 429-433.
17. Langerak AW, Szczepanski T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 1997; 11: 2192-2199.
18. Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood 2001; 98: 165-173.
19. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: Evidence for an autoimmune process. Leuk Res 2001; 25: 1075-1083.
20. Plasilova M, Risitano A, Maciejewski JP. Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases. Hematology 2003; 8: 173-181.
21. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841-851.
22. Asano Y, Maeda M, Uchida N, Yokoyama T, Osaki K, Shimoda K et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 2001; 80: 634-638.
23. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997; 79: 1548-1551.
24. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304-309.
25. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-163.
26. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK et al A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18: 460-465.
27. Tamayose K, Sugimoto K, Ando M, Oshimi K. Disappearance of chromosomal abnormalities and recovery of hematopoiesis after immunosuppressive therapy for hypoplastic refractory anemia with excess of blasts. Blood 2001; 97: 2524.
28. Yamada T, Tsurumi H, Kasahara S, Hara T, Sawada M, Moriwaki H. Immunosuppressive therapy for myelodysplastic syndrome: Efficacy of methylprednisolone pulse therapy with or without cyclosporin A. J Cancer Res Clin Oncol 2003; 129: 485-491.
29. Yoshimi A, Baumann I, Fuhrer M, Bergstrasser E, Gobel U, Sykora KW et al. Immunosuppressive therapy with antithymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia. Haematologica 2007; 92: 397-400.